Burden of illness in idiopathic pulmonary fibrosis

Collard, Harold R.; Ward, Alex; Lanes, Stephan; Hayflinger, D Cortney; Rosenberg, D; Hunsche, Elke

doi:10.3111/13696998.2012.680553

Cited by 175 publications

(185 citation statements)

References 14 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…In general, the prevalence of PH was similar in studies from Europe [18,25,[40][41][42][43][44][45][47][48][49], North America [5,6,26,28,46,[50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67], Asia and Africa [37,[68][69][70][71][72][73][74][75], although the majority of evidence was reported from North America (n=23, 53%). Across studies, the prevalence of PH among IPF patients ranged from 3% to 86%; most estimates tended to be between 30% and 50% (figure 3) [25, 43, 44, 47, 50, 52-66, 68, 71-73].…”

Section: Pulmonary Hypertensionmentioning

confidence: 99%

“…The reported prevalence of COPD ranged from 6% to 67% (figure 2) ( prevalence ranges by country: 12% [21] to 51% [18] in Europe, 8% [26] to 67% [31] in North America and 34% [36] to 65% [34] in Asia). The highest reported proportion of patients with emphysema (67%) was among IPF patients with isolated diffusing capacity of the lung for carbon monoxide (DLCO) decrease, therefore probably overestimating the prevalence of emphysema in IPF [31].…”

Section: Respiratory Comorbidities Copdmentioning

confidence: 99%

“…The prevalence of COPD (including emphysema) was reported in 23 studies (online supplementary table S1), of which eight were from Europe [18][19][20][21][22][23][24][25], eight were from North America [6,[26][27][28][29][30][31][32], six were from Asia [33][34][35][36][37][38] and one was from South America (Brazil) [39]. The reported prevalence of COPD ranged from 6% to 67% (figure 2) ( prevalence ranges by country: 12% [21] to 51% [18] in Europe, 8% [26] to 67% [31] in North America and 34% [36] to 65% [34] in Asia).…”

Section: Respiratory Comorbidities Copdmentioning

confidence: 99%

See 2 more Smart Citations

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

et al. 2015

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is associated with a fatal prognosis and manifests in patients over 60 years old who may have comorbidities. The prevalence and impact of comorbidities on the clinical course of IPF is unclear.This systematic literature review examined the prevalence of comorbidities and mortality associated with comorbidities in IPF patients. Relevant observational studies published in English from January 1990 to January 2015 identified via MEDLINE and EMBASE were included; bibliographies of articles were also searched.Among the 126 studies included, prevalence of pulmonary hypertension (PH) was 3-86%, 6-91% for obstructive sleep apnoea, 3-48% for lung cancer and 6-67% for chronic obstructive pulmonary disease (COPD). Nonrespiratory comorbidities included ischaemic heart disease (IHD) (3-68%) and gastrooesophageal reflux (GER) (0-94%). Mortality was highest among patients with IPF and lung cancer. Most studies assessed relatively small samples of patients with IPF.PH, COPD, lung cancer, GER and IHD are significant comorbidities; differences in IPF severity, case definitions and patient characteristics limited the comparability of findings. The identification and prompt treatment of comorbidities may have a clinically significant impact on overall outcome that is meaningful for patients with IPF. @ERSpublications Identification and prompt treatment of comorbidities has a clinically significant impact on outcome for IPF patients

show abstract

Section: Pulmonary Hypertensionmentioning

confidence: 99%

Section: Respiratory Comorbidities Copdmentioning

confidence: 99%

Section: Respiratory Comorbidities Copdmentioning

confidence: 99%

See 1 more Smart Citation

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Since the disease affects older individuals, it might initially be perceived by patients and primary-care physicians as a sign of deconditioning or pre-existing comorbidity [9]. In a Danish cohort, the median duration of symptoms before first visit to a referral centre was 28 months [10].…”

Section: Introductionmentioning

confidence: 99%

The lived experience with idiopathic pulmonary fibrosis: a qualitative study

et al. 2016

View full text Add to dashboard Cite

The disease course in idiopathic pulmonary fibrosis (IPF) is variable, but patients experience a progressive decline in lung function and increased symptom burden leading to death. Little is known about the patients' experience and their needs during the disease course or about the burden on family caregivers. Both patients and family caregivers face an altered life as the disease progresses. The aim of our study was to increase knowledge of life with IPF for patients and family caregivers.This study had a qualitative descriptive design using in-depth dyadic interviews with IPF patients (n=25) and family caregivers (n=24). We used the five-step analysis from the framework method and analysed the data on three levels: the patient, the family caregivers and couple level.The following six themes emerged as the main results: information and disclosure, reactional dyssynchrony, perpetual vigilance, emotional ambivalence, gradual and tacit role shift, and adapted coping strategies.Our findings suggest that IPF patients need information at the time of diagnosis, but some issues should be paced as the disease progresses. A palliation plan was demanded by patients and their caregivers. Further efforts are required to provide palliative care to IPF patients starting at the time of diagnosis. @ERSpublications IPF patients and caregivers need information, but full disclosure should be gradual and palliation initiated early

show abstract

“…I pazienti con IPF, rispetto ai pazienti senza IPF, sono infatti associabili ad un incremento dell'utilizzo di risorse sanitarie e generano importanti costi, sia prima che dopo la diagnosi. Il tasso di ricovero, le giornate di degenza e le visite ambulatoriali per tutte le cause nei pazienti con IPF sono circa due volte più elevati, rispetto a quelli della popolazione generale della stessa età [65].…”

Section: Impatto Economico Della Ipfunclassified

[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]

Belisari¹,

Bettoni

Cortesi

et al. 2017

View full text Add to dashboard Cite

To date, there are few therapeutic answers for Idiopathic pulmonary fibrosis (IPF) and only two pharmacological treatments have a marketing authorization for this disease. Recently nintedanib (Ofev®) has been authorized as a new therapeutic option and its economic profile has been evaluated by international Health Technology Assessment (HTA) bodies. IPF has important implications for everyday life of patients and their carers, negatively influencing their quality of life and bringing heavy economic burden to the NHS and to the entire society. It is, therefore important to consider these aspects for the Italian environment and to perform a pharmacoeconomic evaluation to define the efficiency of nintedanib in IPF by means of a Cost-Utility Analysis (CUA). As IPF is a chronic and progressive disease, a lifetime Markov model has been therefore developed with health states describing the patient’s condition as a combination of lung function and exacerbation history. The cohort entered in the model at different Forced Vital Capacity (FVC%) predicted health states, without exacerbation. The Clinical data used to perform this CUA were derived from clinical trials and the relative efficacy of nintedanib versus the comparator (pirfenidone) was then obtained from a Network Meta-Analysis (NMA) combining data reported in each primary study (INPULSIS 1-2 and TOMORROW trials for nintedanib, and CAPACITY and ASCEND trials for pirfenidone, respectively). At base-case, treatment with nintedanib resulted in a slightly lower estimated total cost vs pirfenidone, better safety profile and lower risk of acute exacerbations with an advantage in Quality Adjusted Life years (QALYs) gained. These results were confirmed by the sensitivity analysis. Although nintedanib appears to be a valuable option for the NHS to treat IPF patients, future data evidence, as long-term or real-life data, will help to confirm these results.[In Italian]

show abstract

Burden of illness in idiopathic pulmonary fibrosis

Abstract: Patients with idiopathic pulmonary fibrosis experience increased comorbidity, healthcare resource utilization, and direct medical costs compared to controls.

Cited by 175 publications

References 14 publications

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review

The lived experience with idiopathic pulmonary fibrosis: a qualitative study

[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]

Contact Info

Product

Resources

About